Cure8 research brief
Cure8 research brief
People with pediatric‑onset Crohn’s disease on long‑term thiopurines may be at risk for severe EBV‑related complications like HLH; recognizing HLH early can be lifesaving. The case supports considering EBV screening before immunosuppression and rapid multidisciplinary care if suspected.
Pediatric and adult patients with pediatric‑onset Crohn’s disease, parents/caregivers, gastroenterologists, hematologists/oncologists, and clinicians managing immunosuppression.
This report highlights a rare but life‑threatening complication (EBV‑HLH) that can occur in immunosuppressed patients with pediatric‑onset Crohn’s disease, particularly those on thiopurines such as azathioprine.
Early consideration of HLH is important when patients with IBD develop persistent high fevers, cytopenias, and markedly elevated ferritin rather than assuming an IBD flare. The authors recommend pre‑treatment EBV serologic screening and close interdisciplinary care (gastroenterology, hematology/oncology, infectious disease) for at‑risk patients.
The case also illustrates that HLH treatment may require multiple immunosuppressive or cytotoxic agents and that drug toxicities (here, PRES) can complicate management.
This is a single case report (abstract level). Recommendations such as routine EBV screening before thiopurine use are discussed by the authors but this article alone cannot define practice guidelines. PRES was a treatment complication in this case, underscoring that HLH therapy can have serious side effects.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.